DPP4 and heart failure: However, possible detection bias due to the awareness and alertness of heart failure related to the use of DPP-4 inhibitors was less likely because the two clinical trials (i.e., SAVOR-TIMI53 and EXAMINE) reporting an unexpectedly higher risk of heart failure hospitalization related to the use of saxagliptin and alogliptin were published in 2013 [1, 2] and the follow-up of the present study cohort was actually ended before this year.